- Home
- BGI vs LPCN Comparison
BGI vs LPCN Comparison
Compare BGI & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- LPCN
- Stock Information
- Founded
- BGI 1879
- LPCN 1997
- Country
- BGI Canada
- LPCN United States
- Employees
- BGI N/A
- LPCN N/A
- Industry
- BGI
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- BGI
- LPCN Health Care
- Exchange
- BGI Nasdaq
- LPCN Nasdaq
- Market Cap
- BGI 23.4M
- LPCN 16.4M
- IPO Year
- BGI 2005
- LPCN N/A
- Fundamental
- Price
- BGI $1.16
- LPCN $3.30
- Analyst Decision
- BGI
- LPCN Strong Buy
- Analyst Count
- BGI 0
- LPCN 1
- Target Price
- BGI N/A
- LPCN $10.00
- AVG Volume (30 Days)
- BGI 208.7K
- LPCN 15.2K
- Earning Date
- BGI 11-27-2024
- LPCN 05-08-2025
- Dividend Yield
- BGI N/A
- LPCN N/A
- EPS Growth
- BGI N/A
- LPCN N/A
- EPS
- BGI N/A
- LPCN N/A
- Revenue
- BGI $131,596,265.00
- LPCN $7,922,926.00
- Revenue This Year
- BGI N/A
- LPCN N/A
- Revenue Next Year
- BGI N/A
- LPCN N/A
- P/E Ratio
- BGI N/A
- LPCN N/A
- Revenue Growth
- BGI 4.01
- LPCN N/A
- 52 Week Low
- BGI $0.93
- LPCN $2.91
- 52 Week High
- BGI $3.49
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- BGI 44.14
- LPCN 43.33
- Support Level
- BGI $1.08
- LPCN $2.96
- Resistance Level
- BGI $1.21
- LPCN $3.62
- Average True Range (ATR)
- BGI 0.13
- LPCN 0.26
- MACD
- BGI 0.02
- LPCN 0.05
- Stochastic Oscillator
- BGI 55.85
- LPCN 54.78
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.